Modivcare Recognizes DAB Transport for Compassionate Care and Commitment to Community Health
Modivcare Inc. (the 'Company' or 'Modivcare') (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, proudly recognizes DAB Transport's outstanding commitment to service central Georgia with compassion and flexibility.
Founded in 2020 by Regina Mcrae, a licensed professional counselor with nearly two decades of experience in mental health care, DAB Transport was born out of a desire to continue helping people in a way that best served their needs. What began with two drivers and two vehicles has rapidly grown into a trusted operation with 15 drivers serving 5–6 counties and managing up to 600 non-emergency medical transportation (NEMT) trips per week.
Named after her three children – Derick, Arianna, and Breonna – DAB Transport remains a small but mighty provider known for its personal approach and deeply involved service model. One powerful example is the company's work transporting young adults involved in a Laurens County program supporting young adults with mental health needs. One passenger, who once mentioned wanting to work during her rides, later pursued employment, crediting Mcrae's encouragement and support for helping her take that step.
'I started DAB Transport as a way to continue making a difference after experiencing burnout from high-intensity mental health crisis work,' said Mcrae. 'Whether it's dialysis patients whose families we come to know personally, or young people on the path to independence, we know we're more than just a ride.'
DAB Transport has partnered with Modivcare from the start, relying on the relationship to fuel steady growth in ride volumes while maintaining a flexible, member-centric approach.
'Regina and the DAB Transport team exemplify what it means to go beyond transportation,' said Rodney Taylor, Modivcare's Senior Director - Transportation Operations for Georgia. 'Their ability to adapt and deliver personalized care in the form of safe, timely rides is essential to our mission. They are a shining example of how NEMT can serve as a powerful link in a member's care journey.'
DAB Transport's success is built on strong hiring, operational flexibility, and a shared understanding that every trip can change a life. Mcrae notes that she and her team are always ready to fill gaps, and there have been several instances where she has stepped behind the wheel herself when needed. Life-sustaining care is not optional, so if a driver is sick and can't come to work, the team prides themselves on being able to pivot and still deliver rides even when unpredictable circumstances occur.
To learn more about Modivcare, visit Georgia | Modivcare.
About Modivcare
Modivcare Inc. ('Modivcare' or the 'Company') is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their members. Modivcare's value-based solutions address the social determinants of health (SDoH) by connecting members to essential care services. By doing so, Modivcare helps health plans manage risks, reduce costs, and improve health outcomes. Modivcare serves as a provider of non-emergency medical transportation (NEMT), personal care services (PCS), and in-home monitoring solutions (Monitoring). To learn more about Modivcare, please visit www.modivcare.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250604568089/en/
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA GEORGIA
INDUSTRY KEYWORD: OTHER TRANSPORT PUBLIC TRANSPORT TRANSPORT HEALTH TECHNOLOGY HEALTH INSURANCE TRANSPORTATION MANAGED CARE HEALTH TRAVEL
SOURCE: Modivcare Inc.
Copyright Business Wire 2025.
PUB: 06/04/2025 07:00 AM/DISC: 06/04/2025 06:58 AM
http://www.businesswire.com/news/home/20250604568089/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ('Amylyx' or the 'Company') today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being evaluated in the pivotal Phase 3 LUCIDITY trial, led to a 64% least-squares (LS) mean reduction (p=0.0031) vs. baseline in the composite rate of Level 2 and Level 3 hypoglycemic events in PBH, with more than half of the participants experiencing no events during the treatment period. LUCIDITY is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in approximately 75 participants with PBH following Roux-en-Y gastric bypass surgery. The FDA-agreed-upon primary endpoint of LUCIDITY is reduction in the composite of Level 2 and Level 3 hypoglycemic events. Consistent reductions in composite rate of Level 2 and Level 3 hypoglycemic events also were seen with avexitide 45 mg twice daily studied in the Phase 2b trial and avexitide 30 mg twice daily and 60 mg once daily studied in the Phase 2 PREVENT trial. New pharmacokinetic (PK) and pharmacodynamic (PD) data were also presented demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period. 'Post-bariatric hypoglycemia can profoundly disrupt daily life, requiring individuals to carefully manage meals, social interactions, and routines, often while living in fear of their next hypoglycemic event. The new analysis presented at ENDO 2025 continues to support that avexitide may significantly reduce the frequency of these events,' said Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY trial and Clinical Associate Professor at Stanford University. Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, added, 'Post-bariatric hypoglycemia is a serious and underrecognized condition with no FDA-approved treatments. The data presented show that, in an exploratory analysis from the Phase 2 PREVENT and Phase 2b clinical trials, avexitide significantly reduced the composite rate of Level 2 and 3 hypoglycemic events, including at the 90 mg once daily dose that is being studied in our pivotal Phase 3 LUCIDITY trial. We are particularly encouraged that over half of participants did not experience Level 2 or Level 3 hypoglycemic events during the treatment period. In addition, the pharmacokinetic and pharmacodynamic data demonstrated continuous pharmacologic activity of avexitide 90 mg once daily dose over 24 hours. We continue to be encouraged by avexitide's potential to deliver consistent, meaningful benefit to people living with PBH.' The population PK and PD analyses presented at ENDO 2025 demonstrated that avexitide 90 mg once daily maintained consistent GLP-1 receptor inhibition from morning to midnight and between doses. In vitro potency studies showed an IC₅₀ of approximately 20-30 nM (70-100 ng/mL), indicating robust target inhibition even in the presence of significant levels of GLP-1. PK modeling demonstrated that avexitide plasma levels exceeded IC₅₀ for a full 24-hour period. LUCIDITY was informed by data from five PBH clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant and clinically meaningful reductions in hypoglycemic events. Avexitide was generally well-tolerated, with a favorable safety profile replicated across clinical trials. Completion of recruitment for LUCIDITY is expected in 2025, with a data readout anticipated in the first half of 2026 and, if approved, commercial launch anticipated in 2027. The presentation and posters are available on the ' Presentations ' tab of the Amylyx website. Webcast Information Amylyx will host an investor event today, July 13, 2025, at 6:00 p.m. PT / 9:00 p.m. ET in San Francisco to discuss post-bariatric hypoglycemia and avexitide. A live webcast of the presentation and Q&A portion of the event can be accessed under 'Events and Presentations' in the Investor section of the Company's website, The webcast will be archived and available for replay for 90 days following the event. About Avexitide Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 1 and Phase 2 clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent debilitating hypoglycemic events. In two Phase 2 PBH clinical trials, avexitide demonstrated highly statistically significant reductions in hypoglycemic events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living. About Post-Bariatric Hypoglycemia (PBH) Post-bariatric hypoglycemia (PBH) is a condition that is estimated to affect approximately 8% of people in the U.S. who have undergone the two most common types of bariatric surgery, sleeve gastrectomy and Roux-en-Y gastric bypass (approximately 160,000 people in the U.S.). PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. PBH can cause debilitating hypoglycemic events associated with inadequate supply of glucose to the brain, known as neuroglycopenia. Clinical manifestations can include impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability that can result in major disruptions to independent living. There are no approved therapies for PBH. About the LUCIDITY Trial LUCIDITY (NCT06747468) is an approximately 75-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial includes an up to six-week screening period, including a three-week run-in period, and a 16-week double-blind treatment period. Participants who complete the double-blind period will be eligible to enter an open-label extension (OLE) period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the FDA-agreed upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Safety and tolerability will also be evaluated. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit and follow us on LinkedIn and X. For investors, please visit Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx' expectations regarding: the potential of avexitide as a treatment for PBH; expectations regarding the timing for recruitment completion and topline data readout of the Phase 3 LUCIDITY trial of avexitide in PBH; and expectations regarding timing for potential commercialization of avexitide. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx' program development activities; Amylyx' ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx' ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx' operations, as well as the risks and uncertainties set forth in Amylyx' United States Securities and Exchange Commission (SEC) filings, including Amylyx' Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Associated Press
3 hours ago
- Associated Press
LASE Investors Have Opportunity to Join Laser Photonics Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--Jul 13, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Laser Photonics Corporation ('Laser Photonics' or 'the Company') (NASDAQ: LASE ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Laser Photonics disclosed in a May 29, 2025, SEC filing that it had 'received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC ('Nasdaq') stating that since it had not received the Company's Form 10-Q for the period ended March 31, 2025, and because the Company remains delinquent in filing its Form 10-K for the period ended December 31, 2024 (the 'Initial Delinquent Filing'), the Company does not comply with Nasdaq's Listing Rules for continued listing.' The filing continued, 'the Company has until June 16, 2025, to submit a plan to regain compliance with respect to these delinquent reports.' Based on this news, shares of Laser Photonics fell by more than 6.5% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Schall Law Firm Copyright Business Wire 2025. PUB: 07/13/2025 03:36 PM/DISC: 07/13/2025 03:36 PM
Business Insider
3 hours ago
- Business Insider
JPMorgan Says to Short Tesla (TSLA), Moderna (MRNA), and 7 Other Stocks in 2025
JPMorgan (JPM) has released its list of top short ideas for the second half of 2025, spotlighting stocks it believes are positioned to decline in value. The picks span several sectors, including technology, consumer, healthcare, and financials. Among the most notable names are Tesla (TSLA), Moderna (MRNA), Whirlpool (WHR), and Shake Shack (SHAK). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Nine Stocks JPMorgan Says to Short in H2 2025 Tesla, a $1.01 trillion company, is down around 22% year-to-date. JPMorgan analysts believe its valuation remains elevated relative to the rest of the Magnificent Seven, even with earnings expected to fall for the third consecutive year. Reduced EV subsidies and weak operating margins are part of the concern. There's also skepticism around its robotaxi roadmap, which JPMorgan says lacks sensor redundancy. Meanwhile, Moderna has dropped 19% in 2025 despite a recent bounce of more than 20%. JPMorgan cites continued cash burn, regulatory headwinds, and no clear near-term growth drivers. The firm's analysts do not expect a significant rebound in the stock, though TipRanks data shows an average price target that implies 40% upside. Another notable name is Whirlpool, which is rated Neutral, but JPMorgan sees downside risk following a sharp 38% rally since June. Analyst Michael Rehaut says the stock is trading at a valuation premium of over 15% above its historical averages. While WHR could benefit from U.S. tariffs due to its domestic manufacturing base, Rehaut believes its performance has run ahead of fundamentals. Other stocks on the short list include Shake Shack, which trades at 467 times earnings; Mobileye (MBLY), Intel (INTC), Bumble (BMBL), Comerica (CMA), and Rivian (RIVN). Each carries an Underweight rating from JPMorgan and is flagged for sector-specific challenges or valuation risk. Using TipRanks' Comparison Tool, we've assembled and compared the nine stocks JPM thinks are going to drop. This tool helps you gain a broader perspective on each stock's performance and fundamentals. This list comes at a time when major indexes have bounced back to record highs. The S&P 500 (SPY) and Nasdaq are showing strength, but JPMorgan's cautious picks reflect lingering concern about policy uncertainty and profit outlooks. Investors can track these names closely through TipRanks' analyst consensus, price target forecasts, and Smart Score data to weigh the broader sentiment. As the second half unfolds, JPMorgan's bearish calls offer a watchlist of names where Wall Street sees limited upside and growing risks.
